IP Verse

Protein Delivery In Primary Hematopoietic Cells - EP3250693

EP3250693

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Application Number
EP16744244A
Filing Date
Jan 29, 2016
Status
Patent Maintained As Amended
Nov 17, 2023
Grant Date
Dec 20, 2023
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3250693B2 was granted to The Regents OF The University OF California on Dec 20, 2023 following the initial filing on Jan 29, 2016 under the application number EP16744244A . The current legal status of the patent is Patent Maintained As Amended.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEFeb 28, 2022ADMISSIBLE

Patent Citations New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePatent NumberPatent Link
INTERNATIONAL-SEARCH-REPORTUS2014287509
INTERNATIONAL-SEARCH-REPORTUS2014357530
OPPOSITIONWO2016021972
SEARCHWO2014191128

Non-Patent Literature (NPL) Citations New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- DIEZ, AP et al., "Generation of CD 8+ and CD 4+ T- Cell Response to Dendritic Cells Genetically Engineered to Express the MART-1/Melan-A Gene .", Cancer Res., (19981201), vol. 58, no. 23, pages 5305 - 5309, XP055472185 [Y] 32-33 * ; abstract; page 5307, column 1, paragraph 1 *-
INTERNATIONAL-SEARCH-REPORT- HOMBACH, A et al., "T- Cell Activation by Recombinant Receptors: CD 28 Costimulation Is Required for Interleukin 2 Secretion and Receptor-mediated T- Cell Proliferation but Does Not Affect Receptor-mediated Target Cell Lysis.", Cancer Res., (20010301), vol. 61, no. 5, page 1076 1092, XP055472191 [Y] 36 * ; abstract; page 1076, column 1, paragraph 1 *-
INTERNATIONAL-SEARCH-REPORT- THEMELI, M et al., "Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.", Nat Biotechnol., (20130811), vol. 31, no. 10, pages 1 - 8, XP055143283 [Y] 8 * ; page 1, column 2, paragraph 2; page 7, column 1, paragraph 1; DOI: 10.1038/nbt.2678 *
INTERNATIONAL-SEARCH-REPORT- GUILINGER, JP et al., "Fusion of catalytically inactive Cas9 to Fokl nuclease improves the specificity of genome modification", Nat Biotechnol, (20140425), pages 1 - 17, XP055157221 [Y] 50 * ; abstract; paqe 2, paragraph 4; DOI:10.1038/nbt.2909 *
INTERNATIONAL-SEARCH-REPORT- LIN, YC et al., "Simulation and experimental demonstration of the electric field assisted electroporation microchip for in vitro gene delivery enhancement.", Lab Chip., (20040310), vol. 4, no. 2, pages 104 - 108, XP009190233 [Y] 14-18 * ; page 106, column 2, paragraph 1; page 107, column 1, paragraph 1; figure 1 *
INTERNATIONAL-SEARCH-REPORT- BIKARD, D et al., "Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system.", Nucleic Acids Res., (20130612), vol. 41, no. 15, pages 1 - 9, XP055195374 [Y] 51 * : page 6. column 1, paragraph 2: figure 3: DOI:10.1093/nar/gkt520 *
INTERNATIONAL-SEARCH-REPORT- YANG, L et al., "Optimization of scarless human stem cell genome editing.", Nucleic Acids Res., (20130731), vol. 41, no. 19, pages 1 - 13, XP055113989 [Y] 38-39, 40/38-39, 41/38-39, 42/38-39 * ; page 3, column 2, paragraph 2; DOI: 10.1093/nar/gkt555 *
INTERNATIONAL-SEARCH-REPORT- CHEN, Z et al., "Receptor-mediated delivery of engineered nucleases for genome modification.", Nucleic Acids Res., (20130816), vol. 41, no. 19, pages 1 - 10, XP055472163 [Y] 12 * ; abstract; page 9, column 1, paragraph 5; DOI: 10 1093/nar/gkt710 *
INTERNATIONAL-SEARCH-REPORT- KIM, S et al., "Highly Efficient RNA-Guided Genome Editing in Human Cells via Delivery of Purified Cas9 Ribonucleoproteins ( and Supplemental information).", Genome Res., (20140402), vol. 24, no. 6, pages 1012 - 1019, XP055277723 [Y] 1-39, 40/37-39, 41/37-39, 42/37-39, 48-54, 59-63 * ; abstract; page 1012, column 1-paragraph 1, column 2-paragraph 2; page 1013, column 1-paragraphs 1 2, column 2-paragraphs 1,3; page 1014, column 1-paragraph 2, column 2-paragraph 2; page 1017, column 2, paragraph 1 - page 1018, column 1, paragraph 2; page 1018, column 1-paragraph 5; supplemental In *
INTERNATIONAL-SEARCH-REPORT- BRUSKO, TM et al., "Human Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene Transfer.", PLoS One., (20100722), vol. 5, no. 7, pages 1 - 12, XP055330448 [Y] 1-39, 40/37-39, 41/37-39, 42/37-39, 48-54, 59-63 * ; abstract; page 3, column 1, paragraph 2; page 8, column 2, paragraph 6 - page 9, column 1, paragraph 2; DOI:10.1371/journal.pone.0011726. *
INTERNATIONAL-SEARCH-REPORT- LIU, J et al., Cell -Penetrating Peptide-Mediated Delivery of TALEN Proteins via Bioconjugation for Genome Engineering., (20140120), vol. 9, no. 1, pages 1 - 7, XP055396351 [Y] 13 * ; abstract; page 1, column 1, paragraph 1; page 6, column 1, paragraph 1; DOI: 10.1371/journal.pone.0085755. *
OPPOSITION- Lonza, "Amaxa® Human CD34+ Cell Nucleofector® Kit", Brochure, (20090801), pages 1 - 4, XP055904236-
OPPOSITION- Lonza, "Amaxa® Human T Cell Nucleofector® Kit ", Brochure, (20090801), pages 1 - 5, XP055904218-
OPPOSITION- Lonza, "Amaxa® Nucleofector® Technology - Do you have cells that are difficult-to-transfect?", Booklet, (20100501), pages 1 - 12, XP055904214-
OPPOSITION- Mandal et al., "Efficient Ablation of Genes in Human Hematopoietic Stem and Effector Cells using CRISPR/Cas9", Cell Stem Cell, AMSTERDAM, NL , (20141106), vol. 15, no. 5, doi:10.1016/j.stem.2014.10.004, ISSN 1934-5909, pages 643 - 652, XP055560200
OPPOSITION- Roth et al., "Reprogramming human T cell function and specificity with non-viral genome targeting", Nature, London, (20180711), vol. 559, no. 7714, doi:10.1038/s41586-018-0326-5, ISSN 0028-0836, pages 405 - 409, XP036544239
OPPOSITION- Schumann et al., "Generation of knock-in primary human T cells using Cas9 ribonucleoproteins", Proceedings of the National Academy of Sciences, (20150727), vol. 112, no. 33, doi:10.1073/pnas.1512503112, ISSN 0027-8424, pages 10437 - 10442, XP055277999
OPPOSITION- Kim et al., "Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins", Genome Research, US , (20140402), vol. 24, no. 6, doi:10.1101/gr.171322.113, ISSN 1088-9051, pages 1012 - 1019, XP055277723
OPPOSITION- Qasim et al., "Progress and prospects for engineered T cell therapies", British Journal of Haematology, Hoboken, USA, (20140617), vol. 166, no. 6, doi:10.1111/bjh.12981, ISSN 0007-1048, pages 818 - 829, XP071097104
SEARCH- PIETRO GENOVESE ET AL, "Targeted genome editing in human repopulating haematopoietic stem cells", NATURE, GB, (20140612), vol. 510, no. 7504, doi:10.1038/nature13420, ISSN 0028-0836, pages 235 - 240, XP055277712 [A] 1-21 * the whole document *
SEARCH- KATHRIN SCHUMANN ET AL, "Generation of knock-in primary human T cells using Cas9 ribonucleoproteins", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20150727), vol. 112, no. 33, doi:10.1073/pnas.1512503112, ISSN 0027-8424, pages 10437 - 10442, XP055277999 [XP] 1-21 * the whole document *
SEARCH- ZHONG CHEN ET AL, "Receptor-mediated delivery of engineered nucleases for genome modification", NUCLEIC ACIDS RESEARCH, (20130816), vol. 41, no. 19, doi:10.1093/nar/gkt710, ISSN 0305-1048, pages e182 - e182, XP055472163 [Y] 1-21 * the whole document *
SEARCH- S. KIM ET AL, "Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins", GENOME RESEARCH, US, (20140402), vol. 24, no. 6, doi:10.1101/gr.171322.113, ISSN 1088-9051, pages 1012 - 1019, XP055277723 [YD] 1-21 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents